User profiles for Eric H. Farber-Eger
Eric Farber-EgerVerified email at vumc.org Cited by 1749 |
Clinical and biological insights into combined post-and pre-capillary pulmonary hypertension
Background : Pulmonary hypertension (PH) is a common and morbid complication of left
heart disease with 2 subtypes: isolated post-capillary pulmonary hypertension (Ipc-PH) and …
heart disease with 2 subtypes: isolated post-capillary pulmonary hypertension (Ipc-PH) and …
Prognostic effect and longitudinal hemodynamic assessment of borderline pulmonary hypertension
…, M Xu, S Huang, FE Harrell, EH Farber-Eger… - JAMA …, 2017 - jamanetwork.com
Importance Pulmonary hypertension (PH) is diagnosed by a mean pulmonary arterial
pressure (mPAP) value of at least 25 mm Hg during right heart catheterization (RHC). While …
pressure (mPAP) value of at least 25 mm Hg during right heart catheterization (RHC). While …
Multiancestry genome-wide association study of aortic stenosis identifies multiple novel loci in the Million Veteran Program
Background: Calcific aortic stenosis (CAS) is the most common valvular heart disease in
older adults and has no effective preventive therapies. Genome-wide association studies (…
older adults and has no effective preventive therapies. Genome-wide association studies (…
Association of mild echocardiographic pulmonary hypertension with mortality and right ventricular function
…, J French, S Huang, T Thayer, EH Farber-Eger… - JAMA …, 2019 - jamanetwork.com
Importance Current guidelines recommend evaluation for echocardiographically estimated
right ventricular systolic pressure (RVSP) greater than 40 mm Hg; however, this threshold …
right ventricular systolic pressure (RVSP) greater than 40 mm Hg; however, this threshold …
Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects
…, M Talati, JP Fessel, EH Farber-Eger… - European …, 2017 - Eur Respiratory Soc
Increased oestrogen is a strong epidemiological risk factor for development of pulmonary
arterial hypertension (PAH) in patients, associated with metabolic defects. In addition, …
arterial hypertension (PAH) in patients, associated with metabolic defects. In addition, …
Arrhythmia variant associations and reclassifications in the eMERGE-III sequencing study
…, CM Shaffer, CG Vanoye, RR Desai, EH Farber-Eger… - Circulation, 2022 - Am Heart Assoc
Background: Sequencing Mendelian arrhythmia genes in individuals without an indication
for arrhythmia genetic testing can identify carriers of pathogenic or likely pathogenic (P/LP) …
for arrhythmia genetic testing can identify carriers of pathogenic or likely pathogenic (P/LP) …
Hemodynamic evidence of vascular remodeling in combined post-and precapillary pulmonary hypertension
…, EL Brittain, QS Wells, EH Farber-Eger… - Pulmonary …, 2016 - journals.sagepub.com
Although commonly encountered, patients with combined postcapillary and precapillary
pulmonary hypertension (Cpc-PH) have poorly understood pulmonary vascular properties. The …
pulmonary hypertension (Cpc-PH) have poorly understood pulmonary vascular properties. The …
Common ancestry-specific ion channel variants predispose to drug-induced arrhythmias
…, GE Davogustto, BD Lowery, EH Farber-Eger… - Circulation, 2022 - Am Heart Assoc
Background: Multiple reports associate the cardiac sodium channel gene (SCN5A) variants
S1103Y and R1193Q with type 3 congenital long QT syndrome and drug-induced long QT …
S1103Y and R1193Q with type 3 congenital long QT syndrome and drug-induced long QT …
[HTML][HTML] Genome-wide association analysis and Mendelian randomization proteomics identify drug targets for heart failure
…, BR Ferolito, M Pietzner, EH Farber-Eger… - Nature …, 2023 - nature.com
We conduct a large-scale meta-analysis of heart failure genome-wide association studies (GWAS)
consisting of over 90,000 heart failure cases and more than 1 million control …
consisting of over 90,000 heart failure cases and more than 1 million control …
Renin-angiotensin-aldosterone system modulates blood pressure response during vascular endothelial growth factor receptor inhibition
…, MM Shuey, A Manouchehri, EH Farber-Eger… - Cardio Oncology, 2019 - jacc.org
Objectives This study postulated that antihypertensive therapy with renin-angiotensin-aldosterone
system (RAAS) inhibition may mitigate vascular endothelial growth factor inhibitor (…
system (RAAS) inhibition may mitigate vascular endothelial growth factor inhibitor (…